Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343839 | 0.81 | ACHE (0.48) | ACHECKS1BSKP1SKP2GPR119 | |
| SCHEMBL14355878 | 0.80 | NCF1 (0.49) | — | |
| SCHEMBL7981893 | 0.80 | GAA (0.56) | ACHECKS1BSKP1SKP2DTYMK | |
| SCHEMBL8567620 | 0.79 | ACHE (0.47) | ACHECKS1BSKP1SKP2DTYMK | |
| SCHEMBL8881052 | 0.78 | ACHE (0.48) | ACHECKS1BSKP1SKP2GPR119 | |
| SCHEMBL615074 | 0.78 | CHRM2 (0.52) | ACHECKS1BSKP1SKP2DTYMK | |
| SCHEMBL5331546 | 0.77 | SMARCA2 (0.46) | ACHECKS1BSKP1SKP2GPR119 | |
| SCHEMBL416461 | 0.77 | ACHE (0.51) | ACHECKS1BSKP1SKP2GPR119 | |
| SCHEMBL2733360 | 0.77 | CYP3A4 (0.60) | DTYMKGPR119POLBSMN1; SMN2 | |
| SCHEMBL110163 | 0.77 | NCF1 (0.51) | ACHECKS1BSKP1SKP2DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | ACHE 3483/4885GBA1 2758/4885CKS1B 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.